Christine Parseghian, M.D.
Christine M. Parseghian, MD
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Clinical Interests
Localized and Metastatic Colorectal Cancer, Anti-EGFR Refractory Colorectal Cancer, RAS Mutated Colorectal Cancer
Education & Training
Degree-Granting Education
| 2012 | Tufts University School of Medicine, Boston, Massachusetts, US, MD |
| 2007 | Harvard University, Cambridge, Massachusetts, US, Neurobiology, BA |
Postgraduate Training
| 2015-2018 | Clinical Fellowship, Hematology/Oncology Fellow, U.T. MD Anderson Cancer Center, Houston, Texas |
| 2012-2015 | Clinical Residency, Internal Medicine Residency, Ronald Reagan University of California, Los Angeles, California |
Licenses & Certifications
| 2018 | American Board of Medical Oncology |
| 2016 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024
Administrative Appointments/Responsibilities
Biostatistics Chair Search Committee Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present
Member, Cancer Center Support Grant Program (CCSG), Houston, TX, 2022 - Present
Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Institutional Committee Activities
Committee Member, Medical Staff Committee, 2022 - Present
Committee Member, Junior Faculty Advisory Committee, 2018 - Present
Fellow, Dolores Zohrab Liebmann Fellow in Graduate Studies, 2008 - 2012
Community Service, Leopold Schepp Foundation Scholar for commitment to community service, 2008 - 2009
Fellow, David F. Noonan Tufts Summer Research, 2008 - 2009
Clinical Assistant, USAID and Armenian Medical Association, 2005 - 2006
Honors & Awards
| 2022 | Patient Experience Top 10% Recognition Provider |
| 2020 - 2022 | Andrew Sabin Family Foundation Award |
| 2019 - 2024 | NIH/NCI Gastrointestinal SPORE Career Enhancement Program Award, NIH/NCI |
| 2019 - 2024 | Gastrointestinal SPORE Career Enhancement Program Award 2019-2021 |
| 2018 - 2024 | 2018 Conquer Cancer Foundation of ASCO Merit Award |
| 2013 - 2014 | Commendation for Excellence in Medical Student Teaching |
| 2012 - 2014 | Solomon Research Scholar |
| 2012 | Tufts University School of Medicine Research Honors |
| 2012 | William Dameshek Award for Research Excellence in Hematology |
| 2012 | William Dameshek Award in Internal Medicine |
| 2007 | Harvard Foundation Distinguished Senior Award for Excellence in Leadership and Academic Achievement |
| 2005 - 2006 | Harvard Foundation Award for Contributions to Intercultural and Race Relations |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2018. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR Rechallenge. Conference. Houston, TX, US.
- 2018. Clinical and Translational Strategies to Address Acquired EGFR Resistance in Metastatic Colorectal Cancer. Conference. U.T. MD Anderson Institutional Grand Rounds. Houston, TX, US.
Regional Presentations
- 2017. Phase I Trial of Pembrolizumab in Combination with Encorafenib and Cetuximab in BRAF Mutated CRC. Conference, US.
National Presentations
- 2025. Best of ASCO Annual Meeting 2025. Invited. Minneapolis, MN, US.
- 2025. ASCO Highlights of the Day Colorectal Cancer. Invited, US.
- 2024. Recent Advances in Colorectal Cancer 2024 Updates in Hematology and Oncology. Invited. Houston, Texas, US.
- 2022. Phase 2 Study of Anti-EGFR Rechallenge Therapy with Panitumumab with or without Trametinib in Advanced Colorectal Cancer. Invited. ASCO Annual Meeting, US.
- 2021. Targeted Therapies Based on Sequencing in Colorectal Cancer. Invited. Innovative Cancer Therapy for Tomorrow, US.
- 2021. Rarity of Acquired Mutations After First-Line Therapy with Anti-EGFR Therapy Invited talk/seminar (Presenter). Invited, US.
- 2018. Anti-EGFR resistant clones decay exponentially after progress: Implications for anti-EGFR Rechallenge. Invited. ASCO Annual Meeting, US.
- 2017. Under-reporting of Research Biopsies from Clinical Trials in Oncology. Mini symposium: Advancing Clinical Trial Design in Regulatory Science and Policy. Invited, US.
International Presentations
- 2024. Overcoming Acquired Resistance to Anti-EGFR in Colorectal Cancer. Invited. Bermuda, US.
- 2024. Can We Improve Outcomes for KRAS MT and BRAF MT Colorectal Cancer?. Invited. CRC Satellite Symposium. Barcelona, US.
- 2023. Future Approaches to BRAF V600E Mutated Colorectal Cancer. Invited. Beirut, LB.
- 2022. Future Approaches to BRAF V600E Mutated Colorectal Cancer. Meet the Expert Series. Invited. Future Approaches to BRAF V600E Mutated Colorectal Cancer. Meet the Expert Series. Beirut, LB.
- 2022. Rechallenge with Cetuximab. Invited. Brazil, US.
- 2022. Going the Extra Mile: Building in an Additional Line of Treatment for RAS/RAF Wildtype Colorectal Cancer with Anti-EGFR Rechallenge. Invited. Paris.
- 2021. Targeted Therapies in Metastatic Colorectal Cancer. Invited, US.
- 2021. Rarity of Acquired Mutations After First-Line Therapy with Ant Oral Poster Discussion Session-EGFR Therapy. Invited. ASCO Annual Meeting, US.
- 2018. Anti-EGFR resistant clones decay exponentially after progress Oral Poster Discussion Session: Implications for anti-EGFR Rechallenge. Invited. 2018 ASCO Annual Meeting, US.
Formal Peers
- 2013. Course Instructor. Los Angeles, CA, US.
Grant & Contract Support
| Date: | 2025 - 2032 |
| Title: | Open-label phase 2 study of Avutometinib (RAF/MEK clamp) in combination with Defactinib (FAK inhibitor) and Cetuximab in patients with unresectable, anti-EGFR-refractory advanced colorectal cancer |
| Funding Source: | Verastem |
| Role: | PI |
| ID: | 2023-0997 | PID16435 |
| Date: | 2024 - 2026 |
| Title: | A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations. NCT06412198, Stand Up 2 Cancer/BMS/Regeneron |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| ID: | 2023-1002 |
| Date: | 2023 - Present |
| Title: | EMB01X201; Phase Ib/II, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Gastrointestinal Cancer. NCT05176665 Shanghai EpimAb Biotherapeutics Co |
| Funding Source: | Shanghai EpimAb Biotherapeutics Co |
| Role: | PI |
| ID: | 2021-1073 |
| Date: | 2023 - Present |
| Title: | Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer who have previously received EGFR or BRAF-directed therapy. NCT05985954 |
| Funding Source: | BioMed Valley Discoveries/Lilly |
| Role: | PI |
| ID: | 2023-0254 |
| Date: | 2020 - 2027 |
| Title: | Open-label Phase Ib/II Study of Cetuximab Administered in Combination with LY3214996 (ERK 1/2 Inhibitor) or Cetuximab in Combination with LY3214996 and Abemaciclib in Patients with Metastatic, Anti-EGFR-Refractory Colorectal Cancer |
| Funding Source: | Eli Lilly and Company |
| Role: | PI |
| ID: | 2019-1016 | PID11309 |
| Date: | 2019 - 2023 |
| Title: | Optimizing Anti-Rechallenge Therapy in Advance Colorectal Cancer |
| Funding Source: | Andrew Sabin Family Foundation Fellowship |
| Role: | PI |
| ID: | 2021-00058939 |
| Date: | 2019 - 2022 |
| Title: | Optimizing Anti-EGFR Rechallenge Therapy in Advanced Colorectal Cancer |
| Funding Source: | Gastrointestinal SPORE Career Enhancement Program |
| Role: | PI |
| Date: | 2017 - 2024 |
| Title: | Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination with Trametinib in anti-EGFR Refractory Stage IV Colorectal Cancer Patients |
| Funding Source: | Amgen Inc |
| Role: | PI |
| ID: | 2016-0338 | PID6180 |
Selected Publications
Peer-Reviewed Articles
- Morris VK, Parseghian CM, Bahrambeigi V, Abdelfattah N, Xiao L, Agrawal A, Lin K, Raghav KP, Wolff RA, Dasari A, Huey RW, Kee BK Overman MJ, Willis JA, Le PH, Escano M, Baig YC, Pan K, Tam AL, Foo WC, Shen L, Lee HM, Gallup TD, Margain C, Gallup D, Branchi V, Rajapakshe KI, Guerrero PA, Wang J, Corcoran RB, Yun K, Maitra A, Kopetz S. Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable, BRAFV600E metastatic colorectal cancer. Cancer Cell, 2025. e-Pub 2025.
- Dasari A, Pellatt AJ, Bent A, Hornstein N, Parseghian CM, Huey RH, Raghav RP, Morris VK, Overman MJ, Morelli P, Willis J, Le P, Shen JP, Kee B, Eluri M, Higbie V, Alfaro-Muniz K, Aziz K, Kell R, Sun R, Kopetz S. A Phase II Trial of TAS-102 in Colorectal Cancer Patients with ctDNA-Defined Minimal Residual Disease Post-Adjuvant Therapy: INTERCEPT-TT. JCO Precis Oncol, 2025. e-Pub 2025.
- Riedl, JM, Fece de la Cruz, F, Lin, JJ, Parseghian, C, Kim, JE, Matsubara, H, Barnes, H, Caughey, BA, Norden, BL, Morales-Giron, AA, Kushner, EW, Ehnstrom, S, Nakamura, H, Patel, PS, Ellis, H, Pappas, L, Vakaris, A, Gainor, J, Kopetz, S, Klempner, SJ, Parikh, AR, Hata, AN, Heist, RS, Corcoran, RB. Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors. Annals of Oncology 36(6):682-692, 2025. e-Pub 2025. PMID: 39914665.
- Pattalachinti VK, Haque E, Yousef M, Yousef A, Chowdhury S, Overman M, Parseghian CM, Morris VK, Kee B, Huey RW, Raghav K, Court CM, Shen JP. BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. NPJ Precis Oncol 9(1):38, 2025. e-Pub 2025. PMID: 39910160.
- Alshenaifi JY, Vetere G, Maddalena G, Yousef M, White MG, Shen JP, Vilar E, Parseghian C, Dasari A, Morris VK, Huey R, Overman MJ, Wolff R, Raghav KP, Willis J, Alfaro K, Futreal A, You YN, Kopetz S. Mutational and co-mutational landscape of early onset colorectal cancer. Biomarkers 30(1):64-76, 2025. e-Pub 2025. PMID: 39761813.
- Villarreal OE, Xu Y, Tran H, Machado A, Prescod D, Anderson A, Minelli R, Peoples M, Martinez AH, Lee HM, Wong CW, Fowlkes N, Kanikarla P, Sorokin A, Alshenaifi J, Coker O, Lin K, Bristow C, Viale A, Shen JP, Parseghian C, Marszalek JR, Corcoran R, Kopetz S. Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer. bioRxiv, 2025. e-Pub 2025. PMID: 39896605.
- Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
- Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR Jr, Tang C, Msaouel P, Ludmir EB. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials. Cancer Res Commun 4(8):2183-2188, 2024. e-Pub 2024. PMID: 39099199.
- Johnson B, Morris V, Wang X, Dasari A, Raghav K, Shen JP, Lee MS, Huey R, Parseghian C, Willis J, Wolff R, Drusbosky LM, Overman MJ, Kopetz S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel) 16(4), 2024. e-Pub 2024. PMID: 38398128.
- Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
- Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
- Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg 277(5):813-820, 2023. e-Pub 2022. PMID: 35797554.
- Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
- Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 41(3):101200JCO2201423, 2023. e-Pub 2022. PMID: 36351210.
- Chowdhury, S, Gupta, R, Millstein, J, Lin, K, Haridas, V, Zeineddine, MA, Parseghian, C, Lenz, HJ, Kopetz, S, Shen, JP. Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer. JCO Precision Oncology 7, 2023. e-Pub 2023. PMID: 37487150.
- Parseghian, C, Eluri, M, Kopetz, S, Raghav, KS. Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer. Frontiers in Cell and Developmental Biology 11, 2023. e-Pub 2023. PMID: 37791069.
- Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
- Ibraheim MK, Lo J, Gupta R, Parseghian C, Patel AB. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients. Support Care Cancer 30(10):8051-8058, 2022. e-Pub 2022. PMID: 35771289.
- Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Pre-diagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
- Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
- Johnson, B, Haymaker, CL, Parra Cuentas, ER, Solis Soto, LM, Wang, X, Thomas, J, Dasari, NV, Morris, VK, Raghav, KS, Vilar Sanchez, E, Kee, BK, Eng, C, Parseghian, C, Wolff, RA, Lee, Y, Lorenzini, D, Laberiano Fernandez, C, Verma, A, Lang, W, Wistuba, II, Futreal, A, Kopetz, S, Overman, MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal for immunotherapy of cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
- Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
- Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
- Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
- Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian CM, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precision Oncology 5:613-621, 2021. e-Pub 2021. PMID: 34250391.
- Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res 98:106445, 2020. e-Pub 2020. PMID: 32937250.
- Favazza LA, Parseghian CM, Kaya C, Nikiforova MN, Roy S, Wald AI, Landau MS, Proksell SS, Dueker JM, Johnston ER, Brand RE, Bahary N, Gorantla VC, Rhee JC, Pingpank JF, Choudry HA, Lee K, Paniccia A, Ongchin MC, Zureikat AH, Bartlett DL, Singhi AD. KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. Mod Pathol 33(9):1832-1843, 2020. e-Pub 2020. PMID: 32376853.
- Gay CM, Parseghian CM, Byers LA. This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. Cancer Cell 37(1):5-7, 2020. e-Pub 2020. PMID: 31951562.
- Clifton K, Rish TA, Parseghian CM, Raymond VM Dasari A, Pereira AA, Willis J, Loree JM, Bauer TM, Chae YK, Sherill G, Fanta P, Grothey A Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S Morris V. Identification of ACtionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precision Oncology, 2019. e-Pub 2019.
- Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019. e-Pub 2019.
- Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of Innate and Acquired Resistance to anti-EGFR therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res, 2019. e-Pub 2019. PMID: 31263029.
- Parseghian CM, Tam AL, Yao J, Ensor J, Ellis LM, Raghav K, Overman MJ. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol 5(3):402-405, 2019. e-Pub 2019. PMID: 30383128.
- Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2019. PMID: 30462160.
- Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914034.
- Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AAL, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris V. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 33015522.
- Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudo progression in Colorectal and Pancreatic Tumors Treated with Immunotherapy. J Immunother 41(6):284-291, 2018. e-Pub 2018. PMID: 29668571.
- Parseghian CM, Raghav K, Wolff RA, Ensor J, Yao J, Ellis LM, Tam AL, Overman MJ. Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res 23(21):6450-6457, 2017. e-Pub 2017. PMID: 28754815.
- Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
- Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian CM, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clin Cancer Res 23(16):4578-4591, 2017. e-Pub 2017. PMID: 28400427.
- Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian CM, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 117(9):2567-76, 2011. e-Pub 2011. PMID: 21068437.
- Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 17(6):584-96, 2010. e-Pub 2010. PMID: 20541703.
Invited Articles
- Eluri M, Kopetz S, Parseghian CM. Truncal dynamics may trump : serial ctDNA to predict early therapeutic response. Clin Cancer Res 29(2):1-OF 10, 2023. e-Pub 2022. PMID: 36378102.
- Horn RA, Tannenbaum D, Morris VK, Johnson B, Overman MJ, Parseghian CM, Kopetz S, Eng C, Rogers JE, Raghav K, Dasari A. Reporting of patient characteristics and use of stratification factors in phase III trials for metastatic colorectal cancer: Urgent need for standardization. J Clin Oncol 2019 37(suppl), 2019. e-Pub 2019.
Review Articles
- Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e 2213588, 2022. e-Pub 2022. PMID: 35608860.
- Megerdichian C, Olimpiadi Y, Hurvitz SA. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev 40(5):614-25, 2014. e-Pub 2014. PMID: 24560997.
- Megerdichian CL, Rees VW, Wayne GF, Connolly GN. Internal tobacco industry research on olfactory and trigeminal nerve response to nicotine and other smoke components. Nicotine Tob Res 9(11):1119-29, 2007. e-Pub 2007. PMID: 17978985.
Abstracts
- Vetere G, Sun R, Morris VK, Dasari A, Kee B, Shen JP, Willis J, Morella MP, Sorokin A, Kanikarla P, Wolff RA, Overman MJ, Raghav KP, Vilar-Sanchez E, Huey RW, Higbie VS, Le PH, Baig YC, Kopetz S, Parseghian CM. Open-label phase Ib/II study of Cetuximab (CET) plus LY3214996 with or without Abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC). J Clin Oncol 43(16), 2025. e-Pub 2025.
- Shen L, Parseghian CM, Zhang Y, Chen Z, Qin Y, Zhang W, Deng Y, Pan H, Gu S, Changzheng L, Wang R, Ren F, Lu Q, Sun X, Zhu Y. EMB-01, an EGFR/cMET bispecific antibody, in metastatic colorectal cancer: Results from an International Phase Ib/II study. Cancer Res 85((8_Supplement_2)), 2025. e-Pub 2025.
- Parseghian CM, Lee JK, Quintanilha J, Schrock AB, Graf R, Pasquina L, Sivakumar S, Oxnard G, Tukachinsky H, Klempner SJ, Kopetz S. Potential Mechanisms of Acquired Resistance to Anti-EGFR Monoclonal Antibody (mAb) Therapy Detected in Liquid Biopsies from Patients with Advanced Colorectal Cancer. J Clin Oncol 42, 2024. e-Pub 2024.
- Parseghian CM, Vilar Sanchez E, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Raghav KP, Dasari A, Kee BK, Wolff RA, Shen JP, Kopetz S. Phase 2 Study of Anti-EGFR Rechallenge Therapy with Panitumumab with or without Trametinib in Advanced Colorectal Cancer. ASCO Annual Meeting, 6/2022 40(16), 2022. e-Pub 2022.
- Parseghian CM, Sun R, Woods MN, Napolitano S, Alshenaifi J, Willis J, Nunez SK, Sorokin A, Marie PK, Singh Raghav KP, Morris VK, YC Shen JP, Sanchez EV, Rehn M, Ang A, Troiani T, Kopetz S. Resistant Mechanisms to anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Varies by Regimen and Line of Therapy. ASCO Annual Meeting, 6/2022 40(16), 2022. e-Pub 2022.
- Parseghian CM, Sun R, Napolitano S, Morris VK, Henry J, Willis J, Sanchez EV, Singh Raghav KP, Ang A, Kopetz S. Rarity of acquired mutations (MTs) after first-line therapy with anti-EGFR therapy (EGFRi). Journal of Clinical Oncology ASCO Annual Meeting 2021 39(15), 2021. e-Pub 2021.
- Parseghian CM, Beutner K, Boedigheimer M, Ruff P, Price TJ, Kim TW, Fakih M, Ang A. Circulating tumor DNA (ctDNA) heterogeneity as first- and third-line treatment in patients (pts) with metastatic colorectal cancer (mCRC) treated with panitumumab. GI ASCO Annual Meeting, 2020. e-Pub 2020.
- Parseghian CM, Willis J, Morris V, Raghav K, Dasari A, Raymond V, Lanman R, Overman MJ, Kopetz S. Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA selective pressure. ASCO Annual Meeting, 2019. e-Pub 2019.
- Rich TA, Clifton K, Raymond VM, Dasari A, Raghav K, Parseghian CM, Lanman RB, Kopetz S, Morris VK. Association between gene fusions and anti-EGFR resistance signature in colorectal cancer. J Clin Oncol(3564), 2019. e-Pub 2019.
- Parseghian CM Loree JM, Morris V, Pereira AA, Vilar Sanchez E, Kee B, Raghav K, Dasari A, Wu J, Raymond V, Banks KC, Talasaz AA, Lanman RB, Overman MJ, Kopetz S. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
- Parseghian CM, Patnana M, Bhosale P, Hess K, Kopetz S, Overman MJ, Naing A, Piha-Paul SA, Subbiah V, Hong D, Le H, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Cancer Patients Treated with Immunotherapy. GI ESMO Annual Meeting, 2017. e-Pub 2017.
- Parseghian CM, Raghav K, Wolff RA, Yao J, Ellis LM, Tam AL, Overman MJ. Under-reporting of Research Biopsies from Clinical Trials in Oncology. Minisymposium: Advancing Clinical Trial Design in Regulatory Science and Policy. AACR Annual Meeting(3595), 2017. e-Pub 2017.
- Thierry AR, Pastor B, Jiang ZQ, Katsiampoura A, Parseghian CM, Loree JM, Overman MJ, Sanchez C, El Messaoudi S, Ychou M, Kopetz S. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. AACR Annual Meeting, 2017. e-Pub 2017.
Book Chapters
- Parseghian, CM, Bent, AH. Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond, 293-299, 2022.
- Parseghian CM. Colorectal Liver Metastases. In: Targeted Therapy Beyond EGFR and VEGF, 2022.
- Parseghian CM. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology. Fourth Edition, 2021.
Patient Reviews
CV information above last modified August 04, 2025